As previously disclosed in the Current Report on Form 8-K filed by ABIOMED, Inc., with the U.S. Securities and Exchange Commission (the “SEC”) on November 1, 2022, the Company is party to an Agreement and Plan of Merger, dated as of October 31, 2022 (the “Merger Agreement”), with Johnson & Johnson and Athos Merger Sub, Inc. In accordance with the terms of the Merger Agreement, on December 21, 2022, the Company and Todd A. Trapp, the Company's Chief Financial Officer, enter into termination agreement.